Clinical effects of multi-oil versus pure soybean oil-based lipid emulsions for preterm infants: An observational

Xing Li1, Rui Zhao1, Hai-Feng Lv2

  • 1Department of Pharmacy, Qiantang Campus, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang Uni-versity, Hangzhou, China.

Insights

Multi-oil-based lipid emulsions (SMOFlipid) showed improved clinical efficacy in preterm infants compared to soybean oil-based emulsions (Intralipid). SMOFlipid was linked to reduced retinopathy of prematurity and shorter hospital stays, suggesting benefits for neonatal health outcomes.

Area of Science:

  • Neonatalogy
  • Clinical Nutrition
  • Pediatric Gastroenterology

Background:

  • Conventional soybean oil-based intravenous lipid emulsions (SO-ILEs) contain high polyunsaturated fatty acids and phytosterols, potentially posing risks to preterm infants.
  • Multi-oil-based intravenous lipid emulsions (MO-ILEs), such as SMOFlipid, are increasingly used in neonatal intensive care units (NICUs).
  • Evidence for MO-ILE benefits over SO-ILEs in very preterm infants remains limited.

Purpose of the Study:

  • To compare the clinical efficacy of SMOFlipid versus Intralipid in preterm infants.
  • To investigate differences in neonatal health outcomes, including morbidity, between the two lipid emulsion types.
  • To evaluate the impact on retinopathy of prematurity (ROP) and hospital length of stay.

Main Methods:

  • Retrospective review of preterm infants (gestational age <32 weeks) requiring parenteral nutrition for ≥14 days between 2016 and 2021.
  • Analysis of infants receiving either SMOFlipid or Intralipid as their primary lipid emulsion.
  • Comparison of morbidity rates, ROP incidence, and hospital length of stay between the two groups.

Main Results:

  • A total of 262 infants were analyzed: 126 received SMOFlipid and 136 received Intralipid.
  • The SMOFlipid group exhibited lower rates of retinopathy of prematurity (ROP) (23.8% vs. 37.5%, p=0.017).
  • Infants receiving SMOFlipid had a significantly shorter hospital stay (median 64.8 days vs. 72.5 days, p<0.001).

Conclusions:

  • SMOFlipid use was associated with higher clinical efficacy in preterm infants compared to SO-ILEs.
  • The findings suggest potential benefits of MO-ILEs in reducing ROP and hospital length of stay.
  • SMOFlipid may be a more advantageous lipid emulsion for optimizing outcomes in preterm neonates.
Abstract